De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Biomerica Beheer
Beheer criteriumcontroles 4/4
De CEO Biomerica's is Zack Irani, benoemd in Apr1997, heeft een ambtstermijn van 27.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 141.25K, bestaande uit 100% salaris en 0% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 6.07% van de aandelen van het bedrijf, ter waarde $ 334.34K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3 jaar en 7.4 jaar.
Belangrijke informatie
Zack Irani
Algemeen directeur
US$141.3k
Totale compensatie
| Percentage CEO-salaris | 100.0% |
| Dienstverband CEO | 27.5yrs |
| Eigendom CEO | 6.1% |
| Management gemiddelde ambtstermijn | 3yrs |
| Gemiddelde ambtstermijn bestuur | 7.4yrs |
Recente managementupdates
Recent updates
Is Biomerica (NASDAQ:BMRA) In A Good Position To Deliver On Growth Plans?
Dec 20
Here's Why We're Watching Biomerica's (NASDAQ:BMRA) Cash Burn Situation
Aug 31We're Keeping An Eye On Biomerica's (NASDAQ:BMRA) Cash Burn Rate
Mar 04Amazon starts selling Biomerica's Aware Breast Self Exam device, EZ Detect test
Sep 29Biomerica: One To Watch Closely For The Future, But From The Sidelines For Now
Sep 09Biomerica reports FY results
Aug 29Biomerica stock jumps after Walmart to begin selling co's Aware Breast Self Exam device
Jul 14Most Shareholders Will Probably Find That The CEO Compensation For Biomerica, Inc. (NASDAQ:BMRA) Is Reasonable
Dec 03Biomerica (NASDAQ:BMRA) Is In A Good Position To Deliver On Growth Plans
Dec 02Is Biomerica Stock A Buy Or Sell After Q4 Earnings? Catalysts To Watch Into 2022
Sep 15Biomerica (BMRA) Investor Presentation - Slideshow
Jun 14Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth
Jun 13Biomerica, Inc.'s (NASDAQ:BMRA) Profit Outlook
Apr 04Should You Review Recent Insider Transactions At Biomerica, Inc. (NASDAQ:BMRA)?
Mar 08Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth
Feb 10The Biomerica (NASDAQ:BMRA) Share Price Has Soared 405%, Delighting Many Shareholders
Jan 15
Biomerica soars as its COVID-19 antigen test wins European nod
Jan 12When Will Biomerica, Inc. (NASDAQ:BMRA) Become Profitable?
Dec 20Biomerica clinical trial for IBS nears enrollment completion
Dec 09How Much Does Biomerica's (NASDAQ:BMRA) CEO Make?
Nov 23Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| May 31 2024 | n/a | n/a | -US$6m |
| Feb 29 2024 | n/a | n/a | -US$6m |
| Nov 30 2023 | n/a | n/a | -US$6m |
| Aug 31 2023 | n/a | n/a | -US$6m |
| May 31 2023 | US$141k | US$141k | -US$7m |
| Feb 28 2023 | n/a | n/a | -US$7m |
| Nov 30 2022 | n/a | n/a | -US$6m |
| Aug 31 2022 | n/a | n/a | -US$5m |
| May 31 2022 | US$491k | US$135k | -US$5m |
| Feb 28 2022 | n/a | n/a | -US$4m |
| Nov 30 2021 | n/a | n/a | -US$7m |
| Aug 31 2021 | n/a | n/a | -US$7m |
| May 31 2021 | US$488k | US$137k | -US$7m |
| Feb 28 2021 | n/a | n/a | -US$6m |
| Nov 30 2020 | n/a | n/a | -US$5m |
| Aug 31 2020 | n/a | n/a | -US$4m |
| May 31 2020 | US$330k | US$137k | -US$2m |
| Feb 29 2020 | n/a | n/a | -US$3m |
| Nov 30 2019 | n/a | n/a | -US$2m |
| Aug 31 2019 | n/a | n/a | -US$2m |
| May 31 2019 | US$329k | US$137k | -US$2m |
| Feb 28 2019 | n/a | n/a | -US$2m |
| Nov 30 2018 | n/a | n/a | -US$2m |
| Aug 31 2018 | n/a | n/a | -US$2m |
| May 31 2018 | US$295k | US$137k | -US$1m |
Compensatie versus markt: De totale vergoeding ($USD 141.25K ) Zack } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).
Compensatie versus inkomsten: De vergoeding van Zack is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Zack Irani (58 yo)
27.5yrs
Tenure
US$141,250
Compensatie
Mr. Zackary S. Irani, also known as Zack, has been Chief Executive Officer of Biomerica Inc. since April 29, 1997 and is its Director and served as its President. He was Chairman of the Board at Biomerica...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 27.5yrs | US$141.25k | 6.07% $ 352.1k | |
| Executive Vice-Chairman of the Board & Corporate Secretary | 25yrs | US$126.25k | 0.47% $ 27.0k | |
| Principal Accounting Officer & CFO | 1.6yrs | US$400.10k | 0% $ 0 | |
| Director of Manufacturing & Technical Operations | no data | geen gegevens | geen gegevens | |
| Chief Commercial Officer | 2.2yrs | geen gegevens | geen gegevens |
3.0yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van BMRA wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | no data | US$141.25k | 6.07% $ 352.1k | |
| Executive Vice-Chairman of the Board & Corporate Secretary | 25yrs | US$126.25k | 0.47% $ 27.0k | |
| Chairman of Strategic Advisory Board | 8.3yrs | geen gegevens | geen gegevens | |
| Member of Strategic Advisory Board | 6.5yrs | geen gegevens | geen gegevens | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 17.5yrs | US$140.27k | 0.42% $ 24.5k | |
| Member of Scientific Advisory Board | 8.3yrs | geen gegevens | geen gegevens | |
| Independent Director | 1.8yrs | US$114.02k | 0% $ 0 | |
| Independent Director | 4.1yrs | US$147.77k | 0.26% $ 15.1k | |
| Chairman of Colorectal Screening Scientific Advisory Board | 2.9yrs | geen gegevens | geen gegevens | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens |
7.4yrs
Gemiddelde duur
66yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van BMRA wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.4 jaar).